James E Galvin, AAIC 2021: Aducanumab for the Treatment of Alzheimer’s Disease
touchNEUROLOGY joins Prof James Galvin (University of Miami Miller School of Medicine, Miami, FL, USA) to discuss aducanumab for the treatment of Alzheimer’s disease, and what this recent accelerated approval might mean for future potential treatments.
Questions
1. Why has the recent FDA accelerated approval of aducanumab for Alzheimer’s disease been so controversial? (00:13-02:00)
2. Why did the EMERGE clinical study meet its primary endpoint, but the ENGAGE study did not? (02:00-04:21)
3. Which patients are most likely to benefit from aducanumab and in whom should it not be used? (04:21-05:13)
4. What are the consequences of this accelerated approval and how will this impact future research for Alzheimer’s disease? (05:13-08:38)
Disclosures: Prof Galvin has no financial or non-financial conflicts of interest to declare in relation to this video.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.
Filmed in coverage of the 2021 AAIC Annual Meeting.
